CR11383A - Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus - Google Patents

Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus

Info

Publication number
CR11383A
CR11383A CR11383A CR11383A CR11383A CR 11383 A CR11383 A CR 11383A CR 11383 A CR11383 A CR 11383A CR 11383 A CR11383 A CR 11383A CR 11383 A CR11383 A CR 11383A
Authority
CR
Costa Rica
Prior art keywords
treatment
glucoquinase
tiadiazol
piridin
activators
Prior art date
Application number
CR11383A
Other languages
English (en)
Inventor
Steven Armen Boyd
Mark Joseph Chicarelli
Kevin Ronald Condroski
Jay Bradford Fell
John P Fischer
Indrani W Gunawardana
Ajay Singh
Timothy M Turner
Eli M Wallace
Ronald Jay Hinklin
Thomas Daniel Aicher
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CR11383A publication Critical patent/CR11383A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporciona compuestos de la formula I en donde R2, R3, R13, L Y D2 son lo definido en la memoria descriptiva, que son utiles en el tratamiento y/o en la prevencion de enfermedades o trastornos mediados por niveles deficientes de actividad de glucocinasa o que se pueden tratar activando glucocinasa
CR11383A 2007-09-21 2010-04-21 Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus CR11383A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97422507P 2007-09-21 2007-09-21

Publications (1)

Publication Number Publication Date
CR11383A true CR11383A (es) 2010-08-13

Family

ID=40250949

Family Applications (2)

Application Number Title Priority Date Filing Date
CR11383A CR11383A (es) 2007-09-21 2010-04-21 Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus
CR20150131A CR20150131A (es) 2007-09-21 2015-03-12 Derivados piridin-2-il-amino-1,2,4-tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20150131A CR20150131A (es) 2007-09-21 2015-03-12 Derivados piridin-2-il-amino-1,2,4-tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus

Country Status (28)

Country Link
US (3) US8212045B2 (es)
EP (4) EP2727910B1 (es)
JP (1) JP5722037B2 (es)
KR (1) KR101566042B1 (es)
CN (1) CN101868459B (es)
AR (1) AR068628A1 (es)
AU (1) AU2008305294B2 (es)
BR (1) BRPI0816881A2 (es)
CA (1) CA2699718C (es)
CO (1) CO6270223A2 (es)
CR (2) CR11383A (es)
DK (1) DK2209778T3 (es)
EA (1) EA019104B1 (es)
ES (2) ES2569734T3 (es)
HR (1) HRP20120814T1 (es)
IL (1) IL204264A (es)
MA (1) MA31779B1 (es)
MX (1) MX2010002772A (es)
MY (1) MY180558A (es)
NZ (1) NZ583538A (es)
PL (1) PL2209778T3 (es)
PT (1) PT2209778E (es)
SI (1) SI2209778T1 (es)
TN (1) TN2010000100A1 (es)
TW (1) TWI423799B (es)
UA (1) UA101166C2 (es)
WO (1) WO2009042435A1 (es)
ZA (2) ZA201002206B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008061108A2 (en) * 2006-11-15 2008-05-22 Forest Laboratories Holdings Limited Phthalazine derivatives
MY180558A (en) 2007-09-21 2020-12-02 Array Biopharma Inc Pyridin-2-yl-amino-1,2,4- theiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
AU2011293584B2 (en) 2010-08-23 2014-07-31 Amgen Inc. Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes
BR112013023054A2 (pt) 2011-03-09 2019-09-24 Daiichi Sankyo Co Ltd composto, composição farmacêutica, ativador da glicocinase, uso de um composto, métodos para ativação da glicocinase, e para o tratamento e/ou prevenção de uma doença
WO2012138776A1 (en) 2011-04-05 2012-10-11 Amgen Inc. Benzodioxepine and benzodioxine compounds that interact with glucokinase regulatory protein for the treatment of diabetes
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013123444A1 (en) 2012-02-17 2013-08-22 Amgen Inc. Sulfonyl compounds that interact with glucokinase regulatory protein
WO2013173382A1 (en) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
WO2013173672A1 (en) 2012-05-18 2013-11-21 Array Biopharma Inc. Method for the preparation of thiadiazoles
CA2890852A1 (en) * 2012-11-09 2014-05-15 Array Biopharma Inc. Crystalline forms of (1s)-1-[5-({3-[(2-methylpyridin-3-yl)oxy]-5-(pyridin-2-ylsulfanyl)pyridin-2-yl}amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol
WO2016059647A2 (en) * 2014-10-13 2016-04-21 SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India) Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
BR112020008727A2 (pt) 2017-10-30 2020-10-20 Neuropore Therapies, Inc. fenil sulfonil fenil triazol tionas substituídas e usos destas
SG11202011881PA (en) * 2018-05-31 2020-12-30 Hua Medicine Shanghai Ltd Pharmaceutical combination, composition and combination formulation comprising glucokinase activator and dpp-iv inhibitor, and preparation method and use thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983246A (en) 1974-04-04 1976-09-28 Fmc Corporation N-(sulfonyloxy) benzimidoyl halides as bactericidal or fungicidal agents
DE2949913A1 (de) * 1979-12-12 1981-06-25 Basf Ag, 6700 Ludwigshafen Azofarbstoffe
EP0300688A1 (en) 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
JPH0228168A (ja) * 1988-04-14 1990-01-30 Sankyo Co Ltd チアゾール誘導体
WO1993017681A1 (en) 1992-03-02 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
WO1993024442A1 (fr) 1992-05-29 1993-12-09 Yamanouchi Pharmaceutical Co., Ltd. Medicament renfermant un derive d'acide benzoique, et nouveau derive d'acide benzoique
JP3056788B2 (ja) 1994-06-24 2000-06-26 ユーロ−セルティーク，エス．エイ． ホスホジエステラーゼｉｖの阻害化合物および阻害方法
GB9908410D0 (en) * 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP1169038B9 (en) * 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
RU2267484C2 (ru) 1999-04-28 2006-01-10 Авентис Фарма Дойчланд Гмбх Производные диариловой кислоты и фармацевтическая композиция на их основе
US6465467B1 (en) * 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
WO2000076984A2 (en) 1999-05-21 2000-12-21 Biovitrum Ab Novel compounds, their use and preparation
JP4144978B2 (ja) 1999-09-09 2008-09-03 富士フイルム株式会社 １，２，４−チアジアゾール誘導体の合成法
CZ2002861A3 (cs) * 1999-09-10 2002-06-12 Merck & Co., Inc. Inhibitory tyrosinkinázy
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
DE60043397D1 (de) 1999-12-28 2010-01-07 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
US6906067B2 (en) * 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
EE200300085A (et) 2000-08-31 2004-12-15 Pfizer Products Inc. Pürasooli derivaadid ja nende kasutamine proteiini kinaasi inhibiitoritena
US20050209297A1 (en) * 2000-08-31 2005-09-22 Pfizer Inc Pyrazole derivatives
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
EP1578341A4 (en) 2000-10-11 2005-09-28 Tularik Inc MODULATION OF THE CCR4 FUNCTION
AU3950802A (en) 2000-12-07 2002-06-18 Cv Therapeutics Inc Abca-1 elevating compounds
AU2002255452B2 (en) 2000-12-21 2006-06-08 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2002258400A1 (en) * 2001-02-16 2002-08-28 Tularik Inc. Methods of using pyrimidine-based antiviral agents
WO2002094264A1 (en) * 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
ATE316088T1 (de) * 2001-06-22 2006-02-15 Merck & Co Inc Tyrosin-kinase inhibitoren
US20040014755A1 (en) * 2002-01-10 2004-01-22 Dhanapalan Nagarathnam Rho-kinase inhibitors
KR100875362B1 (ko) 2002-02-05 2008-12-22 아스텔라스세이야쿠 가부시키가이샤 2,4,6-트리아미노-1,3,5-트리아진 유도체
WO2003078427A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) 2002-03-15 2003-09-29 Binch, Hayley Compositions useful as inhibitors of protein kinases
WO2003078426A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azolylaminoazine as inhibitors of protein kinases
US7091343B2 (en) * 2002-03-15 2006-08-15 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
IL164302A0 (en) 2002-03-29 2005-12-18 Chiron Corp Substituted benzazoles and use thereof as raf kinase inhibitors
JPWO2003091213A1 (ja) * 2002-04-25 2005-09-02 アステラス製薬株式会社 新規なアミド誘導体又はその塩
WO2004000318A2 (en) 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
AU2003268064A1 (en) * 2002-08-09 2004-02-25 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
AU2003272324A1 (en) * 2002-09-10 2004-04-30 Scios Inc. INHIBITORS OF TFGBeta
CN1703408A (zh) 2002-10-03 2005-11-30 诺瓦提斯公司 作为葡糖激酶激活剂、可用于治疗ⅱ型糖尿病的取代的(噻唑－2－基)酰胺或磺酰胺
WO2004041164A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
EP2562158A1 (en) * 2003-02-10 2013-02-27 Vertex Pharmaceuticals Incorporated Processes for the preparation of n-heteroaryl-N-aryl-amines by reacting an N-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
CA2515544A1 (en) 2003-02-11 2004-08-26 Kemia Inc. Compounds for the treatment of viral infection
ATE517887T1 (de) 2003-02-13 2011-08-15 Msd Kk Neue 2-pyridincarbonsäureamidderivate
DE602004014117D1 (de) 2003-03-25 2008-07-10 Vertex Pharma Thiazole zur verwendung als inhibitoren von protein-kinasen
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
JP2007504229A (ja) * 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類
US7470712B2 (en) 2004-01-21 2008-12-30 Bristol-Myers Squibb Company Amino-benzazoles as P2Y1 receptor inhibitors
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
AR049418A1 (es) 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
CN1934100A (zh) 2004-03-23 2007-03-21 万有制药株式会社 取代喹唑啉或吡啶并嘧啶衍生物
EP1737870A1 (en) * 2004-04-02 2007-01-03 Novartis AG Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
EP1742935B1 (en) 2004-04-13 2010-02-24 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
MXPA06011807A (es) 2004-04-13 2007-02-21 Icagen Inc Piridinas policiclicas como moduladores del canal del ion de potasio.
TW200606129A (en) * 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
EP1844023A1 (en) 2004-12-31 2007-10-17 Sk Chemicals Co., Ltd. Quinazoline derivatives for the treatment and prevention of diabetes and obesity
MX2007008434A (es) 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
DE102005025161A1 (de) 2005-06-01 2006-12-07 Phenion Gmbh & Co. Kg Derivate des Pyrimidins und Triazins und deren Verwendung
US7737151B2 (en) * 2005-08-18 2010-06-15 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
RU2008112184A (ru) * 2005-08-31 2009-10-10 Астеллас Фарма Инк. (Jp) Производное тиазола
WO2007038387A2 (en) 2005-09-23 2007-04-05 Yale University Compounds and methods for the treatment of viruses and cancer
CA2628274A1 (en) * 2005-11-01 2007-05-10 Array Biopharma Inc. Glucokinase activators
CN101316843B (zh) 2005-11-03 2013-01-02 顶点医药品公司 用作激酶抑制剂的氨基嘧啶
KR20070052207A (ko) 2005-11-16 2007-05-21 주식회사 엘지생명과학 신규한 ｋｄｒ 억제제
US20070179125A1 (en) * 2005-11-16 2007-08-02 Damien Fraysse Aminopyrimidines useful as kinase inhibitors
WO2007089512A1 (en) * 2006-01-27 2007-08-09 Array Biopharma Inc. Glucokinase activators
EP2543667B1 (en) * 2006-03-24 2015-01-28 Array Biopharma, Inc. A method of preparing 2-aminopyridine analogs as glucokinase activators
US8080669B2 (en) * 2006-05-12 2011-12-20 Ab Science Process for the synthesis of 2-aminoxazole compounds
US20080076800A1 (en) 2006-08-24 2008-03-27 Huang Kenneth H Benzene, Pyridine, and Pyridazine Derivatives
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
DK2091918T3 (en) 2006-12-08 2014-12-01 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
US8431713B2 (en) 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
CN101679405A (zh) 2007-03-23 2010-03-24 阵列生物制药公司 作为葡萄糖激酶活性剂的2-氨基吡啶类似物
US7776857B2 (en) 2007-04-05 2010-08-17 Amgen Inc. Aurora kinase modulators and method of use
US20090012091A1 (en) 2007-07-02 2009-01-08 Kinagen, Inc. Oximide derivatives and their therapeutical application
UY31281A1 (es) 2007-08-13 2009-03-31 Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones.
MY180558A (en) 2007-09-21 2020-12-02 Array Biopharma Inc Pyridin-2-yl-amino-1,2,4- theiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
HRP20120948T1 (hr) 2007-10-09 2012-12-31 Merck Patent Gmbh Derivati piridina koji su korisni kao aktivatori glukokinaze

Also Published As

Publication number Publication date
WO2009042435A1 (en) 2009-04-02
US20150057448A1 (en) 2015-02-26
US9079890B2 (en) 2015-07-14
WO2009042435A8 (en) 2009-10-08
CA2699718C (en) 2014-05-27
KR20100080809A (ko) 2010-07-12
HRP20120814T1 (hr) 2012-11-30
AU2008305294A1 (en) 2009-04-02
US8853409B2 (en) 2014-10-07
ES2393824T3 (es) 2012-12-28
PL2209778T3 (pl) 2013-02-28
SI2209778T1 (sl) 2012-12-31
HK1197821A1 (en) 2015-02-18
US8212045B2 (en) 2012-07-03
ZA201002206B (en) 2011-06-29
US20120277242A1 (en) 2012-11-01
CO6270223A2 (es) 2011-04-20
AU2008305294B2 (en) 2012-11-29
EP3078662A1 (en) 2016-10-12
CR20150131A (es) 2015-04-30
NZ583538A (en) 2012-06-29
EP2727910B1 (en) 2016-03-16
BRPI0816881A2 (pt) 2015-03-17
EA019104B1 (ru) 2014-01-30
EA201000515A1 (ru) 2010-10-29
EP2209778A1 (en) 2010-07-28
TWI423799B (zh) 2014-01-21
PT2209778E (pt) 2012-12-06
EP2727910A1 (en) 2014-05-07
IL204264A (en) 2015-06-30
MA31779B1 (fr) 2010-10-01
MX2010002772A (es) 2010-03-31
TW200914007A (en) 2009-04-01
ZA201102350B (en) 2012-09-26
DK2209778T3 (da) 2012-09-17
CN101868459B (zh) 2013-12-18
US20100204240A1 (en) 2010-08-12
TN2010000100A1 (en) 2011-09-26
CA2699718A1 (en) 2009-04-02
AR068628A1 (es) 2009-11-25
KR101566042B1 (ko) 2015-11-04
JP2010540443A (ja) 2010-12-24
JP5722037B2 (ja) 2015-05-20
EP2573087A1 (en) 2013-03-27
UA101166C2 (ru) 2013-03-11
ES2569734T3 (es) 2016-05-12
HK1145498A1 (en) 2011-04-21
MY180558A (en) 2020-12-02
CN101868459A (zh) 2010-10-20
EP2209778B1 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
CR11383A (es) Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus
ATE521608T1 (de) Glucokinaseaktivatoren
SG170775A1 (en) 2 -aminopyridine analogs as glucokinase activators
WO2008118718A3 (en) 2-aminopyridine analogs as glucokinase activators
TW200740804A (en) Glucokinase activators
DOP2011000279A (es) Derivados de benzofuranilo usados como inhibidores de glucoquinasa
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
CU20090148A7 (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso
UY32968A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de orexina
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
CR20110103A (es) Heteroarilos sustituidos
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
MX2009008284A (es) Compuestos triciclicos y su uso como moduladores de receptor de glucocorticoides.
UA106367C2 (uk) Похідні азадиспіро[3.0.4.1]декану та їх застосування
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
CR8928A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
ECSP088922A (es) Derivados de amino-tiazol y sus usos como agentes antibacterianos
MX2010004309A (es) Moduladores de piperidinil y piperazinil de gamma-secretasa.